In April 2020, the article 'Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding Motif' ( describing the example of using one of the strategies in drug discovery - rational design from the known starting point - was published.

“Compound (P)-14″ is a PI3Kβ isoform-selective lipid kinase inhibitor displaying an excellent pharmacokinetic profile in addition to great cellular potency in various PTEN-deficient tumor cell lines, but significant irreversible off-target toxicity in higher species was observed. It contains substituted quinoline moiety in its backbone.

We have made a set of in-stock Building Blocks, which contain such moiety – the perfect start for your research!